HONG KONG – An Indian court has banned exports of a generic cancer drug, giving Bayer Healthcare Pharmaceuticals Inc. a first victory in an ongoing lawsuit to protect the patent of targeted cancer drug Nexavar (sorafenib), one of its star performers co-developed with Onyx Pharmaceuticals Inc.